Abstract
In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Antiviral Agents / therapeutic use*
-
Benzamides
-
Cytomegalovirus / physiology*
-
Cytomegalovirus Infections / drug therapy*
-
Cytomegalovirus Infections / prevention & control*
-
Female
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Imatinib Mesylate
-
Male
-
Piperazines / therapeutic use*
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / therapeutic use*
-
Retrospective Studies
-
Transplantation Conditioning / methods
-
Virus Activation / drug effects*
-
Young Adult
Substances
-
Antiviral Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Imatinib Mesylate